About Pherecydes Pharma
Pherecydes Pharma is a company based in Romainville (France) founded in 2006. Pherecydes Pharma has raised $16.4 million across 6 funding rounds from investors including GO CAPITAL, European Union and ACE Management. Pherecydes Pharma offers products and services including Live Draw Sydney, Data Sydney, and Betting Services. Pherecydes Pharma operates in a competitive market with competitors including Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others.
- Headquarter Romainville, France
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$16.4 M (USD)
in 6 rounds
-
Latest Funding Round
$56.62 K (USD), Grant
Dec 31, 2021
-
Investors
GO CAPITAL
& 10 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Pherecydes Pharma
Pherecydes Pharma offers a comprehensive portfolio of products and services, including Live Draw Sydney, Data Sydney, and Betting Services.
Real-time streaming of Sydney lottery results for users.
Platform providing historical and current Sydney lotto results.
Online tools for lottery betting and predictions.
People of Pherecydes Pharma
Unlock access to complete
Unlock access to complete
Funding Insights of Pherecydes Pharma
Pherecydes Pharma has successfully raised a total of $16.4M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $56.62 thousand completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Pherecydes Pharma
Pherecydes Pharma has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include GO CAPITAL, European Union and ACE Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Private equity firm focused on energy transition and sustainable investments across Europe.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Pherecydes Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pherecydes Pharma
Investment portfolio details for Pherecydes Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Pherecydes Pharma
Detailed financials for Pherecydes Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pherecydes Pharma Comparisons
Peer comparison for Pherecydes Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Pherecydes Pharma
Pherecydes Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for antimicrobial resistant infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| Locked | Locked | Locked |
Clinical-stage pharmaceutical company focused on developing antibacterials
|
|
| Locked | Locked | Locked |
Drugs for antibiotic-resistant infections and cancer are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for infectious disease and inflammatory indications
|
|
| Locked | Locked | Locked |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
Detailed competitors of Pherecydes Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pherecydes Pharma
Complete news archive for Pherecydes Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pherecydes Pharma
Pherecydes Pharma was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Pherecydes Pharma is headquartered in Romainville, France. It is registered at Romainville, Ile-de-france, France.
Pherecydes Pharma is a funded company, having raised a total of $16.4M across 6 funding rounds to date.
Pherecydes Pharma is a French, early-stage biotech developing bacteriophage treatments against multi-drug resistant bacterial infections. The main bacteria they are targeting include E.coli and P. aeruginosa which are common, and fatal, infections in burn victims. Their phage therapy clinical trial, phase III for burn victims, called PHAGOBURN was funded by the European Govt. (EUR 3.85 M). in Jun.2015, they launched the project PNEUMOPHAGE, targeted at developing phage therapies for acute respiratory infections ventilator-acquired pneumonia caused by P. aeruginosa. Since Jan.2015, they are part of the PHOSA project aimed at developing phage treatments for Diabetic Foot Ulcers and Bone Joint infections, caused by staphylococci species.
Pherecydes Pharma's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Pherecydes Pharma offers Live Draw Sydney, Data Sydney, and Betting Services.
Pherecydes Pharma has 11 investors. Key investors include GO CAPITAL, European Union, ACE Management, Ace management solutions, and EIC Fund.